News

Michael R. Migden, MD, spoke with a group of physicians during a <em>Targeted Oncology </em>live case-based peer perspectives discussion about responses in patients with cutaneous squamous cell carcinoma to immunotherapy treatment.

In an interview with <em>Targeted Oncology</em>,<em> </em>Prithviraj Bose, MD, reviewed his thoughts on identifying and treating progression in myelofibrosis, which he recently presented on during the 2019 SOHO Annual Meeting.&nbsp;&nbsp;

The American Oncology Network, LLC highlights its achievements while celebrating its first year of helping community oncologists.

In an interview with <em>Targeted Oncology</em>, Neil P. Shah, MD, PhD, discussed the latest advancements in the treatment landscape of chronic myeloid leukemia, including the introduction of tyrosine kinase inhibitors. He also addressed some of the challenges both oncologists and patients face in this space.<br /> &nbsp;

In an interview with <em>Targeted Oncology</em>, Jonathan Rosenberg, MD, discussed the ongoing study of durvalumab plus olaparib in patients with metastatic urothelial cancer and other studies that have lain the groundwork for this combination.

In an interview with <em>Targeted Oncology</em>, Michael A. Choti, MD, discussed what he&rsquo;s looking forward to at the 2019 ISGIO Annual Conference and why this meeting is so important to physicians in the field of GI oncology. He also highlighted the surgical approaches to treating patients with HCC from his own experiences as a surgical oncologist, as well as the challenges associated with these treatment options.

The phase III FeDeriCa trial found that a fixed-dose subcutaneous injection of pertuzumab and trastuzumab with hyaluronidase in combination with intravenous chemotherapy was pharmacokinetically noninferior&nbsp;to the standard IV infusions of the regimen in patients with HER2-positive breast cancer.<br /> &nbsp;

The FDA has approved a supplemental New Drug Application for apalutamide for the treatment of patients with metastatic castration-sensitive prostate cancer.

In an interview with <em>Targeted Oncology</em>, Simon Rule, MD, gave an overview of the standard of care for MCL, which he recently presented at the 2019 SOHO Annual Meeting.

The FDA has granted an accelerated approval to the combination of pembrolizumab and lenvatinib for the treatment of patients with advanced endometrial cancer who have disease progression following prior systemic therapy. The indication applies to patients who are not candidates for curative surgery or radiation and who have disease that is not microsatellite instability&ndash;high or mismatch repair deficient.

In an interview with&nbsp;<em>Targeted Oncology</em>, Raymond L. Chai, MD, discussed the latest treatment advancements for thyroid cancer that he has seen over the past few years and how he sees quality of life improving for patients with advanced subtypes of thyroid cancer. He also shared a personal message for oncologists in honor of Thyroid Cancer Awareness Month.

The combination of carfilzomib, dexamethasone, and daratumumab led to a 37% reduction in the risk of progression or death compared with carfilzomib and dexamethasone alone in patients with relapsed or refractory multiple myeloma in the phase III CANDOR trial. According to a press release from Amgen, this met the primary endpoint of progression-free survival for the trial.

A matched retrospective comparison showed that progression-free survival&nbsp; in patients with advanced non-small cell lung cancer and actionable mutations was similar whether treatment went was guided with the use of tissue or circulating tumor DNA analysis with the Guardant360 assay.

The FDA has issued a warning for a rare, but severe, lung inflammation that could be caused by the use of CDK4/6 inhibition in patients with advanced breast cancers.&nbsp;The warning applies to treatment with palbociclib, ribociclib, and abemaciclib specifically, but warnings of the risk of lung inflammation have been approved to be added to the prescribing information for the entire class of CDK4/6 inhibitors.

In an interview with Targeted Oncology, Charles Geyer, MD,&nbsp;discussed the potential role of neratinib as well as other new agents that are coming down the pipeline for the treatment of patients with metastatic HER2-positive breast cancer. He also addressed the biggest challenges oncologists face in managing this disease.

The FDA has granted a priority review to a Biologics License Application for enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced, or metastatic setting and a PD-1/PD-L1 checkpoint inhibitor.

The presence of novel combinations and oral targeted therapies are rising in the frontline treatment setting for patients with chronic lymphocytic leukemia, regardless of age. According to Nitin Jain, MD, ongoing phase III trials will bring additional modifications to the treatment landscape.

In an interview with&nbsp;<em>Targeted Oncology </em>during the 2019 SOHO Annual Meeting, John F. DiPersio, MD, PhD, discussed the challenges in research surrounding immunotherapies for AML, including DARTs, BiTEs, ADCs, and CARs.

In an interview with <em>Targeted Oncology</em>, John V. Heymach, MD, PhD, discussed the phase II study to identify mechanisms of acquired poziotinib resistance and the other available agents for targeting <em>EGFR</em> exon 20&ndash;mutant NSCLC.

In an interview with <em>Targeted Oncology</em>, Yi-Long Wu, MD discussed the results of the INSIGHT study and other agents and combinations for the treatment of patients with <em>EGFR</em>-mutant NSCLC.<br /> &nbsp;

In the phase III QUAZAR AML-001 trial, an investigational oral azacitidine therapy, CC-486, induced a statistically significant improvement in overall survival compared with placebo when used as a maintenance therapy in the treatment of patients with newly diagnosed acute myeloid leukemia who achieved a complete response or CR with incomplete blood count recovery following treatment with induction chemotherapy.

Avelumab demonstrated promising efficacy in treating patients with mismatch repair&ndash;deficient endometrial cancer, according to the results of a phase II study published in the&nbsp;Journal of Clinical Oncology.&nbsp;

Atezolizumab monotherapy demonstrated a statistically significant overall survival benefit in comparison with chemotherapy doublets in patients with untreated advanced non&ndash;small cell lung cancer with high PD-L1 expression and without <em>ALK </em>or <em>EGFR </em>mutations. This met the primary endpoint for the phase III IMpower110 trial, according to initial results release by Genentech, the developer of the PD-L1 inhibitor.

A&nbsp;hazard ratio for overall survival of 0.99 for&nbsp;tivozanib versus sorafenib in patients with&nbsp;refractory metastatic renal cell carcinoma, according to findings from the second prespecified analysis of the TIVO-3 trial, AVEO Oncology announced.

The combination of&nbsp;atezolizumab plus carboplatin and nab-paclitaxel demonstrated a clinical overall survival benefit in a subgroup of patients with&nbsp;advanced squamous non&ndash;small cell lung cancer and a high level of PD-L1 expression in the phase III IMpower131 trial. Final data for this study was presented at the 2019 World Conference on Lung Cancer.

The FDA has accepted a supplemental New Drug Application for the use of neratinib in combination with capecitabine for the treatment of patients with HER2-positive metastatic breast cancer following failure of &ge;2 prior lines of HER2-directed therapy.

Cabazitaxel in combination with carboplatin demonstrated an improvement in progression-free survival in comparison with cabazitaxel alone in men with metastatic castration-resistant prostate cancer. Adverse events were more common with the combination regimen, but the doublet was generally well tolerated.

The FDA has granted a breakthrough therapy designation to tepotinib, an investigational MET inhibitor, for the treatment of patients with metastatic non&ndash;small cell lung cancer harboring a&nbsp;MET&nbsp;exon 14 skipping alteration who have progressed following platinum-based therapy.

In a recent review of the 5-year outcomes from the COMBI-d and COMBI-v trials published in the&nbsp;New England Journal of Medicine, investigators saw long-term benefit with the use of dabrafenib plus trametinib as first-line treatment in about one-third of patients with unresectable or metastatic melanoma and&nbsp;BRAF V600E or V600K mutations.

Treatment with selpercatinib induced responses in 68% of patients with&nbsp;<em>RET&nbsp;</em>fusion&ndash;positive non&ndash;small cell lung cancer, according to findings from the phase I/II LIBRETTO-001 trial.